



UNITED STATES  
NUCLEAR REGULATORY COMMISSION  
REGION I  
475 ALLENDALE ROAD  
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

June 6, 2005

Docket No. 03011222  
Control No. 136887

License No. 37-16554-01

Romaine Niemeyer  
President and CEO  
Holy Spirit Hospital  
503 North 21st Street  
Camp Hill, PA 17011-2288

SUBJECT: HOLY SPIRIT HOSPITAL, LICENSE AMENDMENT, CONTROL NO. 136887

Dear Sr. Niemeyer:

This refers to your license amendment request dated April 10, 2005. Enclosed with this letter is the amended license removing the authorized users you requested.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14). Current NRC regulations and guidance are available at the NRC web site at <http://www.nrc.gov/materials/miau/mat-toolkits.html> and <http://www.nrc.gov/who-we-are/governing-laws.html> or by contacting the Government Printing Office (GPO) toll-free at 1-888-293-6498. The GPO is open from 7:00 a.m. to 9:00 p.m. EST, Monday through Friday (except Federal holidays).

Thank you for your cooperation.

Sincerely,

***Original signed by Penny Lanzisera***

Penny Lanzisera  
Senior Health Physicist  
Medical Branch  
Division of Nuclear Materials Safety

Enclosure:  
Amendment No. 24

cc:  
Douglas E Heim, Radiation Safety Officer

DOCUMENT NAME: G:\Docs\Mailed\Lic Cvr Letter\37-16554-01.136887.06072005.wpd

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	N	DNMS/RI	N	DNMS/RI			
NAME	CHott/CAH7		PLanzisera/PAN					
DATE	6/6/2005		6/6/2005					

OFFICIAL RECORD COPY

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Holy Spirit Hospital</p> <p>2. 503 North 21st Street Camp Hill, Pennsylvania 17011-2288</p>	<p>In accordance with the letter dated April 10, 2005,</p> <p>3. License number 37-16554-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date October 31, 2013</p> <hr/> <p>5. Docket No. 030-11222 Reference No.</p>
---	--

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 700 millicuries</p>
--	---	---

<p>9. Authorized use:</p> <p>A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.</p> <p>B. Any imaging and localization study permitted by 10 CFR 35.200.</p> <p>C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.</p>
---

**CONDITIONS**

- 10. Licensed material shall be used or stored only at the licensee's facilities located at 503 North 21st Street, Camp Hill, Pennsylvania.
- 11. The Radiation Safety Officer for this license is Douglas E. Heim, B.S.
- 12. Licensed material is only authorized for use by, or under the supervision of:
  - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
37-16554-01

Docket or Reference Number  
030-11222

Amendment No. 24

B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Daniel Hottenstein, M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
Richard P. Stewart, M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
George S. Durisek, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction
Harold S. Rabin, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction
Howard S. Bronfman, M.D.	35.100; 35.200; 35.300, except thyroid carcinoma
Barbara Williams-Kunkel, M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
Frank Gallia, M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
J. Russell Croteau, M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
Donald R. Buxton, Jr., M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
Anand S. Jagannath, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction
Keith R. Haidet, M.D.	35.100; 35.200; 35.300
Timothy P. Farrell, M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
Charles Austin, M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
Christine A. Gouldy, M.D.	35.100; 35.200; 35.300, except thyroid carcinoma

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
37-16554-01

Docket or Reference Number  
030-11222

Amendment No. 24

Authorized Users

Material and Use

David N. Auerbach, M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
Elizabeth Anne Bergey, M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
Barbara Bronitsky, M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
Jay D. Goodman, M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
Jeffrey D. Harner, M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
Cindy Jackson, M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
Kiran Kapadia, M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
Erich M. Kim, M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
Paul S. Potok, M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
David R. Tabb, M.D.	35.100; 35.200; Iodine-131 sodium iodide for imaging and localization studies
Robert A. Skotnicki, D.O.	35.100; 35.200
Andreas Wali, M.D.	35.100; 35.200
Donald C. Durbeck, M.D.	35.100; 35.200
Edward C. Brennan, D.O.	35.100; 35.200
Lenke Erki, M.D.	35.100; 35.200
Rajesh M. Dave, M.D.	35.100; 35.200
Ira Sackman, M.D.	35.100; 35.200
Jinan O. Bahia, M.D.	35.100; 35.200
Joseph B. Bellissimo, Jr., M.D.	35.100; 35.200

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
37-16554-01

Docket or Reference Number  
030-11222

Amendment No. 24

<u>Authorized Users</u>	<u>Material and Use</u>
Brian P. Bloom, M.D.	35.100; 35.200
Dean M. Brockmole, M.D.	35.100; 35.200
Stacy J. Castaldi, D.O.	35.100; 35.200
Mark A. Guenin, M.D.	35.100; 35.200
James R. Hills, M.D.	35.100; 35.200
Joachim J. Huerter, M.D.	35.100; 35.200
Judith A. Jozeflak, M.D.	35.100; 35.200
Albert R. Porter, M.D.	35.100; 35.200
Donald J. Schnapf, D.O.	35.100; 35.200
James W. Warren, M.D.	35.100; 35.200
Scott W. Wise, M.D.	35.100; 35.200
Thach N. Nguyen, M.D.	35.200
Robert G. Baily, M.D.	35.200
William P. Apollo, M.D.	35.200
Jeffery S. Mandak, M.D.	35.200
Todd A. Bokelman, M.D.	35.200
Dennis E. Line, M.D.	35.200
David Chang, M.D.	35.200
Steven R. Jones, M.D.	35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
37-16554-01

Docket or Reference Number  
030-11222

Amendment No. 24

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated September 1, 2003  
B. Letter (with attachment) dated October 10, 2003

ML032590573  
ML032901139



For the U.S. Nuclear Regulatory Commission

Date June 6, 2005

By **Original signed by Penny Lanzisera**  
Penny Lanzisera  
Medical Branch  
Division of Nuclear Materials Safety  
Region I  
King of Prussia, Pennsylvania 19406